Professor Johann de Bono
- Honorary Consultant in Medical Oncology
- Professor in Experimental Cancer Medicine
Professor de Bono has both a private and an NHS practice at The Royal Marsden.
Professor Johann de Bono was appointed in July 2003 as Senior Lecturer and Honorary Consultant in Medical Oncology at The Royal Marsden and The Institute of Cancer Research; he is now Professor in Experimental Cancer Medicine. Professor de Bono works in the clinical drug development Phase I trials programme at The Royal Marsden with a particular interest in rationally designed molecular targeted therapies and prostate cancer.
He graduated in medicine from the University of Glasgow in Scotland in 1989, and trained in internal medicine, graduating as a Member of the Royal College of Physicians (MRCP) in 1992. He was then awarded a four-year Cancer Research UK Clinical Research Scholarship which allowed him to pursue a PhD, which he completed in 1997.
He then trained in medical oncology, and was awarded an MSc (Cancer Sciences) in 1999 by Glasgow University. The Royal College of Physicians and Surgeons of Glasgow then awarded him a travelling scholarship that allowed him to pursue further research in 2000 on the statistical issues that pertain to clinical trials of targeted drugs, at the SWOG statistical headquarters at the Fred Hutchinson Cancer Centre in Seattle, USA.
Following this, he pursued further research, developing new anti-cancer drugs in the USA at the Institute for Drug Development in San Antonio and the University of Texas Health Science Centre at San Antonio. Professor de Bono worked in this institution between 2000 and 2003. He was elected a Fellow of the Royal College of Physicians in 2003.
He has received many awards during his career including the American Society for Clinical Oncology (ASCO) Young Investigator Award, an ASCO merit award, a Doris Duke Charitable Foundation Clinician-Scientist Faculty Award and Berlex Oncology Foundation Awards. He has also been awarded research grants from the Cancer Research Campaign, the Medical Research Council, the US National Institute of Health, Stand Up To Cancer, the American Association of Cancer Research (AACR), European Union FP7 funding, Department of Defense (USA), the Federation of European Cancer Societies, the Mesothelioma Applied Research Foundation, the Prostate Cancer Research Foundation, the Prostate Cancer Charity and Cancer Research UK. He was elected as a Member of the Malta Order of Merit in 2009. He received the prestigious ESMO Award in 2012 and was part of the ICR/Royal Marsden team awarded the AACR Team Science Award and he also received an award from the Royal Society of Chemistry for his team’s work in developing abiraterone.
Professor de Bono has been involved in the development of over 50 novel agents over the last five years, many of which are now approved drugs. He is currently running over 20 early clinical trials.